Charlotte's Web Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder
Rhea-AI Summary
Charlotte's Web Holdings (TSX: CWEB) (OTCQX: CWBHF) announced updates on DeFloria 's Phase 1 clinical trial results for AJA001, a treatment targeting autism spectrum disorder (ASD) symptoms. The findings, presented by Dr. Marcel Bonn-Miller at the American College of Neuropsychopharmacology Annual Meeting on December 11, 2024, were described as promising. DeFloria is a joint venture between AJNA BioSciences and Charlotte's Web, focusing on botanical pharmaceutical development.
Positive
- Phase 1 clinical trial for ASD treatment shows promising results
- Results presented at a major scientific conference indicating academic validation
Negative
- None.
News Market Reaction – CWBHF
On the day this news was published, CWBHF gained 5.80%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Promising Findings Presented at the American College of Neuropsychopharmacology Annual Meeting
About AJA001 Oral Solution
AJA001 Oral Solution is being developed by DeFloria as an innovative new botanical drug containing a multi-compound hemp extract with a full spectrum of cannabinoids, bridging the gap between natural wellness products and FDA-regulated medicines that are generally single-compound drugs. Leveraging a proprietary hemp cultivar patented by Charlotte's Web, the Phase 1 trial, designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AJA001, demonstrated that the investigational drug was well-tolerated across a wide dose range. The study provides critical data for determining appropriate dosing protocols that will be used in Phase 2 trials.
Strategic Alignment with Charlotte's Web's Vision
As a co-founder of DeFloria, Charlotte's Web is proud to see its proprietary hemp genetics being utilized to advance innovative therapies for underserved health conditions, such as ASD. The multi-cannabinoid composition of AJA001 underscores the potential of botanical drug development, paving a new category of solutions that provide broad therapeutic efficacy.
"DeFloria's Phase 1 findings represent a significant step toward integrating botanical hemp-based therapies into modern pharmaceutical medicine," said Dr. Marcel Bonn-Miller, Chief Scientific Officer at Charlotte's Web and DeFloria Board Member. "AJA001 isn't just a standalone initiative; it continues Charlotte's Web's long-standing mission grounded in addressing the diverse needs of individuals and families. The safety and pharmacokinetic data from this trial affirm AJA001's potential particularly in a space with limited treatment options. These positive Phase 1 results bring us closer to creating real solutions for this underserved community."
Expanding Charlotte's Web's Leadership in Botanical Science
"DeFloria's Phase 1 results validate our strategic vision of advancing botanical science through pharmaceutical pathways," said Bill Morachnick, CEO of Charlotte's Web. "This milestone demonstrates how our proprietary genetics and expertise in hemp cultivation can create significant value beyond our core wellness business, potentially opening new markets and revenue opportunities for our shareholders."
Clinical and Commercial Opportunities
DeFloria is preparing to submit the Phase 1 trial data as part of its Investigational New Drug (IND) application to the
DeFloria's planned Phase 2 trials in ASD will explore the therapeutic potential of AJA001 in addressing behavioral symptoms and improving quality of life for individuals with the condition. These trials represent a significant step toward potential FDA approval, which would pave the way for broader access to this groundbreaking therapy.
Charlotte's Web continues to prioritize its focus on quality, transparency, and innovation, positioning itself to capitalize on emerging opportunities in regulated botanical drug markets. The progress with DeFloria aligns with the Company's long-term strategy to enhance shareholder value through diversified growth initiatives.
About DeFloria
DeFloria LLC, a collaboration between Charlotte's Web, Inc., AJNA BioSciences PBC, and British American Tobacco PLC (BAT), is on a mission to address crucial healthcare needs through groundbreaking innovations from multi-compound drugs originating in nature. With a combined century of experience in regulatory, research, and quality-controlled standardized manufacturing, DeFloria's ambitious endeavor aims to secure FDA approval for a novel cutting-edge botanical drug developed from Charlotte's Web proprietary hemp genetics that targets a neurological condition identified by the DeFloria leadership and research teams.
About Charlotte's Web Holdings, Inc.
Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in
© Major League Baseball trademarks and copyrights are used with permission of Major League Baseball. Visit MLB.com.
Forward-Looking Information
Certain information provided herein constitutes forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements are typically identified by words such as "may", "will", "should", "could", "anticipate", "expect", "project", "estimate", "forecast", "plan", "intend", "target", "believe" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. This press release includes forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties, and other factors which may cause actual results, levels of activity, and achievements to differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on certain assumptions and analysis by management of the Company in light of its experience and perception of historical trends, current conditions and expected future development and other factors that it believes are appropriate and reasonable.
The material factors and assumptions used to develop the forward-looking statements herein include material risk factors that could cause actual results to differ materially from the forward-looking statements including, among others, general economic and market risks, cyber-security risks and those risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ending December 31, 2023, and other risk factors contained in other filings with the Securities and Exchange Commission available on www.sec.gov and filings with Canadian securities regulatory authorities available on www.sedarplus.ca. The impact of any one risk, uncertainty, or factor on a particular forward-looking statement is not determinable with certainty as these are interdependent, and the Company's future course of action depends on management's assessment of all information available at the relevant time.
Any forward-looking statement in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by applicable law, the Company assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. All forward-looking statements, whether written or oral, attributable to the Company or persons acting on the Company's behalf, are expressly qualified in their entirety by these cautionary statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/charlottes-web-provides-update-on-deflorias-phase-1-results-targeting-autism-spectrum-disorder-302330316.html
SOURCE Charlotte's Web Holdings, Inc.
FAQ
What were the Phase 1 trial results for CWBHF's AJA001 autism treatment?
What is DeFloria's relationship with Charlotte's Web (CWBHF)?
When did CWBHF present their AJA001 autism treatment results?
What condition is CWBHF's AJA001 treatment targeting?
